RecruitingPhase 1 / Phase 2NCT07089121
3
studies recruiting now
as of 7 Sept 2026
5
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
28 Jul 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT04806620
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
RecruitingNCT01793168
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Showing the 3 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Juvenile myasthenia gravis studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Juvenile myasthenia gravis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Juvenile myasthenia gravis
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
14 approved treatments and 36 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Neostigmine Methylsulfate (Bloxiverz)Approved: Pralidoxime Chloride (Contrathion)Approved: Pyridostigmine Bromide (Mestinon)Approved: Guanidine Hydrochloride (Guanidine hydrochloride)Approved: Amifampridine (Ruzurgi)Approved: NeostigmineApproved: Amifampridine Phosphate (Amifampridine serb)Approved: AmbenoniumApproved: EdrophoniumApproved: Rozanolixizumab (Rystiggo)Approved: Zilucoplan Sodium (Zilbrysq)Approved: PyridostigmineApproved: NipocalimabApproved: Efgartigimod Alfa (Efgartigimod alfa component of vyvgart hytrulo)
Phase 3Ravulizumab (Ultomiris)
Phase 3Satralizumab (Enspryng)
Phase 3Batoclimab
Phase 3Sodium Chloride (Aqsia (balanced salt soln))
Phase 3Inebilizumab (Uplizna)
Phase 3Mycophenolate Mofetil (Arzip)
Phase 3Rituximab (Blitzima)
Phase 3Zilucoplan
+ 28 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).